Document is current
Any future updates will be listed below
-
Authors
Shimamura, Munehisa
Kaikita, Koichi
Nakagami, Hironori
Kawano, Tomohiro
Ju, Nan
Hayashi, Hiroki
Nakamaru, Ryo
Yoshida, Shota
Sasaki, Tsutomu
Mochizuki, Hideki
Tsujita, Kenichi
Morishita, Ryuichi
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development
- License Information
-
More Information
Article History
Received: 25 January 2021
Accepted: 24 May 2021
First Online: 1 June 2021
Competing interests
: A patent application for the S100A9 vaccine has been filed (application no. 2017-30327; T.K., M.S., H.N., H.M., R.M.). The Department of Clinical Gene Therapy is financially supported by AnGes MG, Novartis, Shionogi, Boeringher, and Rohto. The Department of Health Development and Medicine is financially supported by AnGes MG and DAICEL. R.M. is a founder and stockholder of AnGes MG and a former board member. The other authors declare no competing interests.
